Meeting Coverage:

American Society of Retina Specialists Annual Meeting

ASRS: 2018

Highlights From the Phase 3 Chroma and Spectri Trials

Show Description +

Carl D. Regillo, MD, FACS, analyzes data from the Chroma and Spectri phase 3 lampalizumab (Roche/Genentech) trials with regard to the effect of baseline characteristics on the progression of geographic atrophy.

Posted: 7/20/2018

Highlights From the Phase 3 Chroma and Spectri Trials

Carl D. Regillo, MD, FACS, analyzes data from the Chroma and Spectri phase 3 lampalizumab (Roche/Genentech) trials with regard to the effect of baseline characteristics on the progression of geographic atrophy.

Posted: 7/20/2018


Please log in to leave a comment.